Erik Sjögren, Assoc. Prof., Ph.D.

Principal Director, PBPK & PBBM Scientific Lead

Portrait-of-Erik-Sjogren_Pharmetheus-2

Bio

  • Joined Pharmetheus in 2017, actively working in client projects, serving as PBPK & PBBM Scientific Lead
  • Expertise includes physiological based pharmacokinetic and biopharmaceutics modeling and simulation, clinical pharmacology, and pediatrics across therapeutic areas
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform research and supervise Ph.D. students. Previously, he worked as Acting Senior Lecturer at Uppsala University, Sweden and Postdoctoral Researcher at AstraZeneca Mölndal, Sweden
  • M.Sc. in Pharmaceutical Sciences (2004), Ph.D. in Pharmaceutical Sciences (2010), Associate Professor in Biopharmaceutics (2016) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Best Practices in Physiologically Based Pharmacokinetic (PBPK) ModelingAccelerating subcutaneous drug development: A mechanistic absorption model for the Open Systems Pharmacology frameworkLarge Language Model-Supported Data Collation: Addressing Accuracy and ReproducibilityBenchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observationsFood effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approachIntegrating in silico epitope prediction and mechanistic QSP modeling for benchmarking immunogenicity riskOpen-source PBPK modeling of artemether for pediatric extrapolations: integrating enzyme ontogeny, CYP2B6 auto-induction and malnutritionModel-based bioequivalence methods open new doors for genericsPrediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) ModelingThe evolving role of in vitro – in vivo correlation in Model-Informed Drug Development: A multi-stakeholder perspectivePhysiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma